Significance of Oxidants and Inflammatory Mediators in Blood of Patients Undergoing Cardiac Surgery

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 22, Issue 3, 2008, Pages 455-467

  Elahi, Maqsood M ^a   Yii, Michael ^b   Matata, Bashir M ^c  

^a BUPA Hospitals   (United Kingdom)

^b ST VINCENT S HOSPITAL   (Australia)

^c LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

cardiopulmonary bypass; coronary heart surgery; hemostasis; inflammation; oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CYTOKINE; OXIDIZING AGENT; OXIDOREDUCTASE; OXYGEN RADICAL; REACTIVE OXYGEN METABOLITE;

DRUG MECHANISM; EXTRACORPOREAL CIRCULATION; HEART SURGERY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MOLECULAR DYNAMICS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR SURGICAL PROCEDURES; HUMANS; INFLAMMATION MEDIATORS; OXIDANTS; REACTIVE OXYGEN SPECIES;

EID: 44149086359     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2007.12.022     Document Type: Review

References (124)

1. Fransen E., Maessen J., Dentener M., et al. Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest 113 (1998) 1290-1295
2. Elahi M.M., Khan J.S., and Matata B.M. Deleterious effects of cardiopulmonary bypass in coronary artery surgery and scientific interpretation of off-pump's logic. Acute Cardiac Care 8 (2006) 196-209
3. Matata B.M., Sosnowski A.W., and Galinanes M. Off-pump bypass graft operation significantly reduces oxidative stress and inflammation. Ann Thorac Surg 69 (2000) 785-791
4. Matata B.M., and Galinanes M. Cardiopulmonary bypass exacerbates oxidative stress but does not increase proinflammatory cytokine release in patients with diabetes compared with patients without diabetes: Regulatory effects of exogenous nitric oxide. J Thorac Cardiovasc Surg 120 (2000) 1-11
5. Plomondon M.E., Cleveland Jr. J.C., Ludwig S.T., et al. Off-pump coronary artery bypass is associated with improved risk-adjusted outcomes. Ann Thorac Surg 72 (2001) 114-119
6. Christen S., Finckh B., Lykkesfeldt J., et al. Oxidative stress precedes peak systemic inflammatory response in pediatric patients undergoing cardiopulmonary bypass operation. Free Radic Biol Med 38 (2005) 1323-1332
7. Elahi M.M., and Matata B.M. Is there a role for free radicals in the systemic inflammatory reaction?. J Cardiothorac Ren Res 1 (2006) 131-133
8. Vita J.A., and Keaney Jr. J.F. Endothelial function: A barometer for cardiovascular risk?. Circulation 106 (2002) 640-642
9. Sorescu D., Weiss D., Lassegue B., et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105 (2002) 1429-1435
10. Franke A., Lante W., Fackeldey V., et al. Proinflammatory and antiinflammatory cytokines after cardiac operation: Different cellular sources at different times. Ann Thorac Surg 74 (2002) 363-370
11. Dybdahl B., Wahba A., Lien E., et al. Inflammatory response after open-heart surgery: Release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 105 (2002) 685-690
12. Muller A.C., Kobold J.E., Tulleken J.G., et al. Leukocyte activation in sepsis; Correlations with disease state and mortality. Intensive Care Med 26 (2000) 883-892
13. Tepaske R., Velthuis H., Oudemans-van Straaten H.M., et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: A randomised placebo-controlled trial. Lancet 358 (2001) 696-701
14. Elahi M.M., Courtney J.M., and Matata B.M. The interaction between reactive oxygen species and proinflammatory cytokines in human blood during extracorporeal circulation. Filtration 1 (2005) 89-94
15. Mayers I., Hurst T., Puttagunta L., et al. Cardiac surgery increases the activity of matrix metalloproteinases and nitric oxide synthase in human hearts. J Thorac Cardiovasc Surg 122 (2001) 746-752
16. Matata B.M., and Galinanes M. Nitric oxide metabolism during cardiopulmonary bypass is altered by exogenous nitric oxide. Circulation 100 (1999) 3152
17. Matata B.M., and Elahi M.M. Peroxynitrite: An intriguing double agent in biology and cardiovascular disease. In: Pandalai S.G. (Ed). Recent Research Developments in Biophysics, Part 1 vol 3 (2004), Transworld Research Network Press, Kerala, India 93-112
18. Elahi M., Chetty G., and Matata B. Ethnic differences in the management of coronary heart disease patients: Lessons to be learned in Indo-Asians. Med Princ Pract 15 (2006) 69-73
19. Biglioli P., Cannata A., Alamanni F., et al. Biological effects of off-pump vs. on-pump coronary artery surgery: Focus on inflammation, hemostasis and oxidative stress. Eur J Cardiothorac Surg 24 (2003) 260-269
20. Dhalla N.S., Elmoselhi A.B., Hata T., et al. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res 47 (2000) 446-456
21. Wachtfogel Y.T., Kucich U., Greenplate J., et al. Human neutrophil degranulation during extracorporeal circulation. Blood 69 (1987) 324-330
22. Elmoselhi A.B., Lukas A., Ostadal P., et al. Preconditioning attenuates ischemia-reperfusion-induced remodeling of Na+-K+-ATPase in hearts. Am J Physiol Heart Circ Physiol 285 (2003) 1055-1063
23. Pyles L.A., Fortney J.E., Kudlak J.J., et al. Plasma antioxidants depletion after cardiopulmonary bypass in operations for congenital heart disease. J Thorac Cardiovasc Surg 110 (1995) 165-171
24. De Backer W.A., Amsel B., Jorens P.G., et al. N-acetylcysteine pretreatment of cardiac surgery patients influences plasma neutrophil elastase and neutrophil influx in bronchoalveolar lavage fluid. Intensive Care Med 22 (1996) 900-908
25. Yusuf S., Dagenais G., Pogue J., et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 154-160
26. Milei J., Forcada P., Fraga C.G., et al. Relationship between oxidative stress, lipid peroxidation, and ultrastructural damage in patients with coronary artery disease undergoing cardioplegic arrest/reperfusion. Cardiovasc Res 73 (2007) 710-719
27. Mehlhorn U., Krahwinkel A., Geissler H.J., et al. Nitrotyrosine and 8-isoprostane formation indicate free radical-mediated injury in hearts of patients subjected to cardioplegia. J Thorac Cardiovasc Surg 125 (2003) 178-183
28. Kawahito K., Kobayashi E., Ohmori M., et al. Enhanced responsiveness of circulatory neutrophils after cardiopulmonary bypass: Increased aggregability and superoxide producing capacity. Artif Organs 24 (2000) 37-42
29. Lahet J.J., Courderot-Masuyer C., Lenfant F., et al. The influence of extracorporeal circulation on the susceptibility of erythrocytes to oxidative stress. Free Radical Res 38 (2004) 683-689
30. Griendling K.K., Sorescu D., and Ushio-Fukai D.M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res 86 (2000) 494-501
31. Fleming I., Michaelis U.R., Bredenkotter D., et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88 (2001) 44-51
32. Dodd J.M., Welsh L.E., Salazar J.D., et al. Effect of NADPH oxidase inhibition on cardiopulmonary bypass-induced lung injury. Am J Physiol Heart Circ Physiol 287 (2004) 927-936
33. Clermont G., Vergely C., Jazayeri S., et al. Systemic free radical activation is a major event involved in myocardial oxidative stress related to cardiopulmonary bypass. Anesthesiology 96 (2002) 80-87
34. Ochoa J.J., Vilchez M.J., Ibanez S., et al. Oxidative stress is evident in erythrocytes as well as plasma in patients undergoing heart surgery involving cardiopulmonary bypass. Free Radical Res 37 (2003) 11-17
35. Gonenc A., Hacisevki A., Bakkaloglu B., et al. Oxidative stress is decreased in off-pump versus on-pump coronary artery surgery. J Biochem Mol Biol 39 (2006) 377-382
36. Elahi M.M., and Matata B.M. Free radicals in blood: evolving concepts in the mechanism of ischemic heart disease. Arch Biochem Biophys 450 (2006) 78-88
37. Volk T., Schmutzler M., Engelhardt L., et al. Effects of different steroid treatment on reperfusion-associated production of reactive oxygen species and arrhythmias during coronary surgery. Acta Anaesthesiol Scand 47 (2003) 667-674
38. Li J.S., Sanders S.P., Perry A.E., et al. Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. Am Heart J 147 (2004) 173-180
39. Pryor W.A. Free radicals in autoxidation and in aging. In: Armstrong D., Sohal R.S., Cutler R.G., et al. (Eds). Free Radicals in Molecular Biology, Aging and Disease (1984), Raven Press Publishers, New York 13-41
40. Obrosova I.G., Mabley J.G., Zsengeller Z., et al. Role of nitrosative stress in diabetic neuropathy: Evidence from studies with peroxynitrite decomposition catalyst. FASEB J 19 (2005) 401-403
41. 2: A pulse radiolysis study. Free Radic Biol Med 19 (1995) 505-510
42. Elahi M.M., and Matata B.M. Blood-dependent redox activity during extracorporeal circulation in health and disease. The Cardiology 1 (2005) 156-157
43. Matata B.M., and Galinanes M. Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA binding capacity. J. Biol Chem 277 (2002) 2330-2335
44. Elahi M.M., Matata B.M., and Hakim N.S. Quiescent interplay between inducible nitric oxide synthase and tumor necrosis factor-alpha: Influence on transplant graft vasculopathy in renal allograft dysfunction. Exp Clin Transplant 4 (2006) 445-450
45. Vos I.H., Joles J.A., Schurink M., et al. Inhibition of inducible nitric oxide synthase improves graft function and reduces tubulointerstitial injury in renal allograft rejection. Eur J Pharmacol 391 (2000) 31-38
46. Jansen P.G., Te Velthuis H., Oudemans-Van Straaten H.M., et al. Perfusion-related factors of endotoxin release during cardiopulmonary bypass. Eur J Cardiothorac Surg 8 (1994) 125-129
47. Elahi M.M., and Matata B.M. Genetic diversity of tumour necrosis factor: Implications on cardiovascular complications of polymorphisms at position -308 in the promoter region. The Cardiology 1 (2005) 179-188
48. Oyama J., Shimokawa H., Momii H., et al. Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo. J Clin Invest 101 (1998) 2207-2214
49. Sato H., Zhao Z.Q., Jordan J.E., et al. Basal nitric oxide expresses endogenous cardioprotection during reperfusion by inhibition of neutrophils-mediated damage after surgical revascularization. J Thorac Cardiovasc Surg 113 (1997) 399-409
50. Zikria B.A., King T.C., Stanford J., et al. A biophysical approach to capillary permeability. Surgery 105 (1989) 625-631
51. Seghaye M.C., Grabitz R.G., Duchateau J., et al. Inflammatory reaction and capillary leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations. J Thorac Cardiovasc Surg 112 (1996) 687-697
52. Elahi M.M., Battula N.R., Hakim N.S., et al. Acute renal failure in patients with ischemic heart disease: Causes and novel approaches in breaking the cycle of self-perpetuating insults abrogated by surgery. Int Surg 90 (2005) 202-208
53. Hill J.H., and Ward P.A. The phlogistic role of C3 leukotactic fragments in myocardial infarcts in rats. J Exp Med 133 (1971) 885-900
54. Walsh M.C., Bourcier T., Takahashi K., et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 175 (2005) 541-546
55. Weisman H.F., Bartow T., Leppo M.K., et al. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249 (1990) 146-151
56. Pemberton M.G., Anderson, Vetvicka V., et al. Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal injury. J Immunol 150 (1993) 5104-5113
57. Wada K., Montalto M.C., and Stahl G.L. Inhibition of complement C5 reduces local and remote organ injury after intestinal ischemia/reperfusion in the rat. Gastroenterology 120 (2001) 126-133
58. Zhao H., Montalto M.C., Pfeiffer K.J., et al. Murine model of gastrointestinal ischemia associated with complement-dependent injury. J Appl Physiol 93 (2002) 338-345
59. Stahl G.L., Xu Y., Hao L., et al. Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol 162 (2003) 449-455
60. Elahi M.M., Elahi M., and Matata B.M. Reactive oxidant species augment complement function in human blood independently of classical and MBL-pathways. Int J Mol Med Adv Sci 1 (2005) 382-391
61. Elahi M.M., Matata B.M., and Galinanes M. Nitric oxide modulates the inflammatory response to extracorporeal circulation of blood through activation of NF-Kappa B. Circulation 101 (2004) 358
62. Elahi M.M., Matata B.M., and Galinanes M. Oxidant species are less effective in modulating proinflammatory cytokines turnover in ischaemic heart disease. J Mol Cell Cardiol 37 (2004) 245
63. Elahi MM, Matata BM: Endogenous rather than exogenous nitric oxide induces proinflammatory cytokines response and NF-κB activation in blood: Evidence from in vitro and in vivo studies. Filtration (in press)
64. Kapoor M.C., and Ramachandran T.R. Inflammatory response to cardiac surgery and strategies to overcome it. Ann Card Anaesth 7 (2004) 113-128
65. Rajas S.G., and Berg G.A. Impact of off-pump coronary artery bypass surgery on systemic inflammation: Current best available evidence. J Card Surg 22 (2007) 445-455
66. Hennein H.A., Ebba H., Rodriguez J.L., et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 108 (1994) 626-635
67. Madden N.J., Demarsico A.J., Schocker L.A., et al. On-pump vs. off-pump coronary artery bypass surgery at a non-academic community hospital: Have biocompatibility improvements eliminated the superiority of off-pump surgery?. Int J Artif Organs 30 (2007) 338-344
68. Li S., Price R., Phiroz D., et al. Systemic inflammatory response during cardiopulmonary bypass and strategies. J Extra Corpor Technol 37 (2005) 180-188
69. Courtney J.M., Matata B.M., Yin H.Q., et al. The influence of biomaterials on inflammatory responses to cardiopulmonary bypass. Perfusion 11 (1996) 220-228
70. Hsu L.C. Biocompatibility in cardiopulmonary bypass. J Cardiothorac Vasc Anesth 11 (1997) 376-382
71. Wang X., Wei M., Laurikka J., et al. The anti-inflammatory effects of diazoxide in coronary artery bypass grafting. Shock 22 (2004) 23-28
72. Wei M., Wang X., Kuukasjarvi P., et al. Bradykinin preconditioning in coronary artery bypass grafting. Ann Thorac Surg 78 (2004) 492-497
73. Liakopoulos O.J., Schmitto J.D., Kazmaier S., et al. Cardiopulmonary and systemic effects of methylprednisolone in patients undergoing cardiac surgery. Ann Thorac Surg 84 (2007) 110-118
74. Sano T., Morita S., Masuda M., et al. Cardiopulmonary bypass, steroid administration, and surgical injury synergistically impair memory T cell function and antigen presentation. Interact Cardiovasc Thorac Surg 2 (2003) 598-602
75. Asimakopoulos G., and Gourlay T. A review of anti-inflammatory strategies in cardiac surgery. Perfusion 18 (2003) 7-12
76. Levy J.H., and Tanaka K.A. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 75 (2003) 715-720
77. Rubens F.D., Nathan H., Labow R., et al. Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass. Ann Thorac Surg 79 (2005) 655-665
78. Chaney M.A., Durazo-Arvizu R.A., Nikolov M.P., et al. Methylprednisolone does not benefit patients undergoing coronary artery bypass grafting and early tracheal extubation. Thorac Cardiovasc Surg 121 (2001) 561-569
79. Wan S., LeClerc J.L., Huynh C.H., et al. Does steroid pretreatment increase endotoxin release during clinical cardiopulmonary bypass?. J Thorac Cardiovasc Surg 117 (1999) 1004-1008
80. Engelman R.M., Rousou J.A., Flack III J.E., et al. Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. Ann Thorac Surg 60 (1995) 801-804
81. Bruins P., te Velthuis H., Yazdanbakhsh A.P., et al. Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96 (1997) 3542-3548
82. Bruins P., te Velthuis H., Eerenberg-Belmer A.J., et al. Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: Studies in patients undergoing cardiac surgery and in vitro. Thromb Haemost 84 (2000) 237-243
83. Fontes M.L., Mathew J.P., Rinder H.M., et al., Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Atrial fibrillation after cardiac surgery/cardiopulmonary bypass is associated with monocyte activation. Anesth Analg 101 (2005) 17-23
84. Halvorsen P., Raeder J., White P.F., et al. The effect of dexamethasone on side effects after coronary revascularization procedures. Anesth Analg 96 (2003) 1578-1583
85. Dietrich W., Schopf K., Spannagl M., et al. Influence of high- and low-dose aprotinin on activation of hemostasis in open-heart operations. Ann Thorac Surg 65 (1998) 70-77
86. Bruda N.L., Hurlbert B.J., and Hill G.E. Aprotinin reduces nitric oxide production in vitro and in vivo in a dose-dependent manner. Clin Sci (Lond) 94 (1998) 505-509
87. Hill G.E., Diego R.P., Stammers A.H., et al. Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations. Ann Thorac Surg 65 (1998) 66-69
88. Henry D.A., Moxey A.J., Carless P.A., et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev (2001) CD001886
89. Sedrakyan A., Treasure T., and Elefteriades J.A. Effects of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 128 (2004) 442-448
90. Levi M., Cromheecke M.E., de Jonge E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints. Lancet 354 (1999) 1940-1947
91. Mangano D.T., Tudor J.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
92. Karkouti K., Beattie W.S., Dattilo K.M., et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 46 (2006) 327-338
93. Mangano D.T., Miao Y., Vuylsteke A., et al., Investigators of The Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 297 (2007) 471-479
94. Sedrakyan A., Atkins D., and Treasure T. The risk of aprotinin: A conflict of evidence. Lancet 367 (2006) 1376-1377
95. Van der Linden P.J., Hardy J.F., Daper A., et al. Cardiac surgery with cardiopulmonary bypass: Does aprotinin affect outcome?. Br J Anaesth 99 (2007) 646-652
96. Kutay V., Noyan T., Ozcan S., et al. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits. J Card Surg 21 (2006) 572-577
97. Wan S., LeClerc J.L., Antoine M., et al. Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: A prospective, randomized study. Ann Thorac Surg 68 (1999) 1230-1235
98. de Vroege R., van Oeveren W., van Klarenbosch J., et al. The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators. Anesth Analg 98 (2004) 1586-1594
99. Hazama S., Eishi K., Yamachika S., et al. Inflammatory response after coronary revascularization: Off-pump versus on-pump (heparin-coated circuits and poly2methoxyethylacrylate-coated circuits). Ann Thorac Cardiovasc Surg 10 (2004) 90-96
100. Seeburger J., Hoffmann J., Wendel H.P., et al. Gene expression changes in leukocytes during cardiopulmonary bypass are dependent on circuit coating. Circulation 112 suppl (2005) I224-I1228
101. Jessen M.E. Pro: Heparin-coated circuits should be used for cardiopulmonary bypass. Anesth Analg 103 (2006) 1365-1369
102. Goudeau J.J., Clermont G., Guillery O., et al. In high-risk patients, combination of antiinflammatory procedures during cardiopulmonary bypass can reduce incidences of inflammation and oxidative stress. J Cardiovasc Pharmacol 49 (2007) 39-45
103. Heyer E.J., Lee K.S., Manspeizer H.E., et al. Heparin-bonded cardiopulmonary bypass circuits reduce cognitive dysfunction. J Cardiothorac Vasc Anesth 16 (2002) 37-42
104. Vocelka C., and Lindley G. Improving cardiopulmonary bypass: Heparin-coated circuits. J Extra Corpor Technol 35 (2003) 312-316
105. de Vroege R., Stooker W., van Oeveren W., et al. The impact of heparin-coated circuits upon metabolism in vital organs: Effect upon cerebral and renal function during and after cardiopulmonary bypass. ASAIO J 51 (2005) 103-109
106. Bando K., Pillai R., Cameron D.E., et al. Leukocyte depletion ameliorates free-radical-mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg 99 (1990) 873-897
107. Warren O., Alexiou C., Massey R., et al. The effects of various leukocyte filtration strategies in cardiac surgery. Eur J Cardiothorac Surg 31 (2007) 665-676
108. Elahi M.M., Lim M.Y., Joseph R.N., et al. Early hemofiltration improves survival in post-cardiotomy patients with acute renal failure. Eur J Cardiothorac Surg 26 (2004) 1027-1031
109. Blauth C.I., Smith P.L., Arnold J.V., et al. Influence of oxygenator type on the incidence and extent of microembolic retinal ischemia during cardiopulmonary bypass. J Thorac Cardiovasc Surg 99 (1990) 61-69
110. Matata B.M., Yin H.Q., Courtney J.M., et al. In vitro blood compatibility evaluation of hollow-fibre membrane using a controlled flow system: A comparative study. Int J Artif Organs 19 (1996) 582-589
111. von Segesser L.K., Weiss B.M., Pasic M., et al. Risks and benefits of low systemic heparinization during open-heart operations. Ann Thorac Surg 58 (1994) 391-398
112. Aldea G.S., Doursounian M., O'Gara P., et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: A prospective, randomized study. Ann Thorac Surg 62 (1996) 410-418
113. Tan J., McClung W.G., and Brash J.L. Nonfouling biomaterials based on polyethylene oxide-containing amphiphilic triblock copolymers as surface-modifying additives: Protein adsorption on PEO-copolymer/polyurethane blends. J Biomed Mater Res A (2007) Sep 26 [Epub ahead of print]
114. Nutter B.T., Stammers A.H., Schmer R.G., et al. The rheological effects of X-Coating with albumin and hetastarch on blood during cardiopulmonary bypass. J Extra Corpor Technol 36 (2004) 36-43
115. Sperling C., Houska M., Brynda E., et al. In vitro hemocompatibility of albumin-heparin multilayer coatings on polyethersulfone prepared by the layer-by-layer technique. J Biomed Mater Res A 76 (2006) 681-689
116. Bonser R.S., Dave J.R., Davies E.T., et al. Reduction of complement activation during bypass by prime manipulation. Ann Thorac Surg 49 (1990) 279-283
117. Takai H., Eishi K., Yamachika S., et al. Demonstration and operative influence of low prime volume closed pump. Asian Cardiovasc Thorac Ann 13 (2005) 65-69
118. Yang Z.M., Wang L., Yuan J., et al. Synthetic studies on nonthrombogenic biomaterials 14: Synthesis and characterization of poly(ether-urethane) bearing a Zwitterionic structure of phosphorylcholine on the surface. J Biomater Sci Polym Ed 14 (2003) 707-718
119. van der Heiden A.P., Goebbels D., Pijpers A.P., et al. A photochemical method for the surface modification of poly(etherurethanes) with phosphorylcholine-containing compounds to improve hemocompatibility. J Biomed Mater Res 37 (1997) 282-290
120. Hsu S.H., Chuang S.C., Chen C.H., et al. Endothelial cell attachment to the gamma irradiated small-diameter polyurethane vascular grafts. Biomed Mater Eng 16 (2006) 397-404
121. Yii M., Gourlay T., Fleming J., et al. Evaluation of Carmeda bioactive surface (CBAS), Duraflo II and a novel nonspecific protease-modified surface using a new in vitro model simulating cardiopulmonary bypass. Perfusion 11 (1996) 229-240
122. Ovrum E., Tangen G., Oystese R., et al. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations. J Thorac Cardiovasc Surg 121 (2001) 324-330
123. Ovrum E., Tangen G., Oystese R., et al. Heparin-coated circuits (Duraflo II) with reduced versus full anticoagulation during coronary artery bypass surgery. J Card Surg 18 (2003) 140-146
124. Flom-Halvorsen H.I., Ovrum E., Brosstad F., et al. Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction. Perfusion 17 (2002) 339-345